464192-28-7

Basic information

• Product Name: 2-Bromo-5-fomylthiazole
• Synonyms: 2-BROMO-5-FORMYLTHIAZOLE;4-BROMOTHIAZOLE-2-CARBALDEHYDE;2-Bromo-5-fomylthiazole;2-Bromo-1,3-thiazole-5-carboxaldehyde 98%;2-Bromo-1,3-thiazole-5-carboxaldehyde;2-Bromo-5-formyl-1,3-thiazole;4-Bromothiazole-2-carboxaldehyde;2-Bromothiazole-5-carboxaldehy
• CAS NO: 464192-28-7
• Molecular Formula: C₄H₂BrNOS
• Molecular Weight: 192.03
• Product Categories: Aldehydes;blocks;Bromides;Thiazoles;Aldehyde;Building Blocks;Thiazole;Organohalides
• Mol File: 464192-28-7.mol

Chemical Properties

• Melting Point: 94-96°C
• Boiling Point: 264.9 °C at 760 mmHg
• Flash Point: 114 °C
• Appearance: White to yellow/Crystalline Powder
• Density: 1.92 g/cm³
• Vapor Pressure: 0.00947mmHg at 25°C
• Refractive Index: 1.665
• Storage Temp.: 2-8°C
• PKA: -0.94±0.10(Predicted)
• CAS DataBase Reference: 2-Bromo-5-fomylthiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-5-fomylthiazole(464192-28-7)
• EPA Substance Registry System: 2-Bromo-5-fomylthiazole(464192-28-7)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-43-36-22
• Safety Statements: 26-36/37/39-36/37
• WGK Germany: 3
• Hazardous Substances Data: 464192-28-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-5-fomylthiazole is used as a reactant for the preparation of thienopyridines, which are potent checkpoint 1 kinase (CHK1) inhibitors. These inhibitors play a crucial role in the development of novel cancer therapeutics, as they help regulate cell cycle progression and DNA damage response, thus contributing to the prevention and treatment of various types of cancer.
Used in Chemical Synthesis:
Due to its unique chemical structure, 2-Bromo-5-fomylthiazole can be utilized as an intermediate in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals. Its reactivity and functional groups make it a valuable building block for creating complex molecules with specific properties and applications.

InChI:InChI=1/C4H2BrNOS/c5-4-6-1-3(2-7)8-4/h1-2H

Upstream product

• 1003-61-8 2-aminothiazole-5-carbaldehyde 
• 687636-93-7 (2-bromothiazole-5-yl)methanol 

Downstream Products

• 726185-68-8 2-piperazin-1-yl-thiazole-5-carboxylic acid methyl ester 
• 1242446-37-2 2-bromo-5-(pyrrolidin-1-ylmethyl)thiazole 
• 396082-02-3 2-phenylethynyl-thiazole-5-carbaldehyde 
• 933683-87-5 2-ethylthiazole-5-carbaldehyde 
• 60587-86-2 2-propyl-5-thiazole-carboxaldehyde 
• 877385-86-9 2-cyclopropylthiazole-5-carbaldehyde 
• 207675-84-1 2-isopropyl-thiazole-5-carbaldehyde 
• 1011-40-1 2-phenyl-1,3-thiazole-5-carbaldehyde 
• 914348-82-6 C₁₁H₉NO₂S 
• 1005-28-3 2-(dimethylamino)thiazole-5-carbaldehyde 
• 914348-80-4 2-(4-fluorophenyl)thiazole-5-carbaldehyde 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein. Compounds AA are modulators of NLRP1 and/or NLRP3

Hetero-aromatic compound and its use in medicine

The invention provides a hetero-aromatic compound or a stereisomer, geometric isomer, tautomer, despinner, nitrogen oxide, hydrate, solvate, metabolite, metabolism precursor and pharmaceutically acceptable salt or prodrug thereof, which is used for treating proliferative diseases. The invention also discloses a pharmaceutical composition containing the compound and an application of the compound or pharmaceutical composition thereof in preparation of a medicine for treating proliferative diseases.

SUBSTITUTED NITROGEN CONTAINING COMPOUNDS

Disclosed are compounds of Formula (I): or a salt thereof, Formula (II) wherein R1 is: or; each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

THIAZOLIDINONE DERIVATIVE

An object of the present invention is to provide thiazolidinone derivatives. More specifically, an object of the present invention is to provide novel compounds having a CDC7 inhibitory action. The present invention provides thiazolidinone derivatives represented by the formula (I) The compounds of the present invention inhibit the CDC7 protein kinase activity, and suppress cell proliferation.

NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS

The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.

1-ACYL-PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS

Anti-viral agents of Formula (I) wherein: A represents hydroxy; D represents aryl or heteroaryl; E represents hydrogen, C1-6alkyl, aryl, heteroaryl or heterocyclyl; G represents hydrogen or optionally substituted C1-6alkyl; J represents C1-6alkyl, heteroc